Inside the research

Moderna, Inc.

MRNA Research profile · latest available data

Price overview

$198.88

▲ +4.06 (+2.1%)

52w hi$198.88
52w lo$22.36
Vol13.90M
As of25 Sep 2026

The Verdict

Hold

Our score +0.01

Short+0.24
Medium+0.14
Long-0.69

computed 2026-09-27

Key fundamentals

Moderna, Inc.

Healthcare · Biotechnology

Market cap$79.40B
Enterprise value$75.55B
Forward P/E-44.50x
EV / EBITDA-34.42x
P / S (ttm)35.64x
Profit margin-141.4%
Return on equity-39.0%
Revenue growth+2.1%
Debt / equity19.04

Layer Breakdown

LayerRawContribution
Fundamental-0.22
Sector+0.13
Technical+0.14
Earnings+0.00
Sentiment+0.00

macro × 1.00 · 2026-09-27

Business overview

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

United States · www.modernatx.com

Risk Metrics

Beta vs SPX1.53
Corr SPX0.17
Annual vol144.0%
Annual ret+118.4%
Sharpe0.82
Max DD-66.5%

Window: 504 trading days (504 obs)

Analyst Coverage

Mean PT$43.37
High / Low$69.00 / $21.00
Median$45.00
Analysts19
Strong Buy2
Buy2
Hold16
Sell1
Strong Sell2

Recent rating actions

2026-05-04UBS→ Neutral
2026-05-04RBC Capital→ Sector Perform
2026-05-04Goldman Sachs→ Neutral
2026-05-04Evercore ISI Group→ In-Line
2026-04-02Barclays→ Equal-Weight
2026-02-23Piper Sandler→ Overweight

Material Events

DateEvent8-K
2026-07-31Earnings Release, Exhibitsread
2026-07-08Officer / Director Change, Reg FD Disclosure…read
2026-05-11Bylaws Amendment, Shareholder Vote…read
2026-05-01Earnings Release, Exhibitsread
2026-03-05Material Agreementread
2026-02-13Earnings Release, Exhibitsread
2026-02-11Reg FD Disclosure, Other Material Event…read
2026-01-12Earnings Release, Reg FD Disclosure…read
2026-01-05Reg FD Disclosure, Exhibitsread
2025-11-24Material Agreement, Material Obligation…read
2025-11-20Reg FD Disclosure, Exhibitsread
2025-11-13Shareholder Voteread

Insider Trades

DateInsiderRoleActionSharesValue
2026-08-06Bancel StephaneChief Executive OfficerOption exercise252.47K$4.83M
2026-08-05Bancel StephaneChief Executive OfficerOption exercise499.25K$9.56M
2026-08-05Bancel StephaneChief Executive OfficerSell187.04K$11.00M
2026-08-05Bancel StephaneChief Executive OfficerSell147.47K$8.29M
2026-08-05Bancel StephaneChief Executive OfficerSell39.89K$2.32M
2026-08-05Bancel StephaneChief Executive OfficerSell124.84K$7.11M
2026-07-15Hoge StephenPresidentOption exercise16.11K$308.51K
2026-07-15Hoge StephenPresidentSell53.34K$3.61M
2026-07-15Hoge StephenPresidentOption exercise37.23K$712.88K
2026-07-02Mock James MChief Financial OfficerOption exercise1.45K—

Flow & Concentration

Insider 180d net-$35.23M
Insider buys / sells0 / 7
Insider biasSellers
13F holders8
Top-5 share99.4%
HHI4,667 (concentrated)

Top Holders

HolderValueShares
Fidelity / FMR LLC$3.63B51.86M
State Street Corp$1.10B15.73M
Citadel Advisors$436.46M6.23M
Capital Research / Capital World$361.90M5.17M
Millennium Management$51.03M728.72K
AQR Capital Management$33.55M479.14K
Bridgewater Associates$807.24K11.53K
T. Rowe Price Group$391.44K5.59M

As of 2026-06-30

SEC Filings

DateFormDoc
2026-08-074view
2026-07-318-Kview
2026-07-3110-Qview
2026-07-164view
2026-07-104view
2026-07-103view
2026-07-088-Kview
2026-07-074view
2026-07-064view
2026-06-303view
2026-06-174view
2026-06-084view
2026-06-084view
2026-06-034view
2026-06-034view

The Long Run

FY 2018–2025 · 8 years

LineLatestCAGRTrend
Revenue$1.94B+51.0%
Operating income-$3.07B+41.1%
Net income-$3.56B—
Cash from ops-$3.12B+193.9%

Indices

S&P 500

Recent Sessions

DateOpenHighLowCloseVol
Sep 25$195.35$202.67$192.51$198.8813.90M
Sep 24$180.60$195.71$180.39$194.8216.61M
Sep 23$183.40$192.31$181.30$182.1117.73M
Sep 22$168.50$187.20$168.30$182.5624.03M
Sep 21$161.05$176.86$159.06$172.9421.02M

Understand the score. Research layers are inputs to a model, and the available data has limits.

Read the methodology →